Stocks in Action USA and International: Uber, Humana, CG Oncology
Reading Time: 3 minutes
CG Oncology (CGON): Phase 3 data show 68% reduced risk of recurrence in bladder cancer! CG Oncology has achieved a significant clinical success with the Phase 3 study PIVOT-006: The drug candidate Cretostimogene lowered the risk of recurrence in patients with intermediate-risk and high-grade T1 bladder cancer by 68% compared to the control group (Hazard Ratio 0.32; p<0.0001). After a median follow-up period of 17 months, no treatment-related adverse events of grade 3 or higher were reported, and no corresponding therapy discontinuations occurred....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

